Fig. 2: Dynamic evolution of TCRβ repertoire throughout a Lenti-HPV-07 prime-boost immunization regimen.
From: T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector

a Timeline of prime-boost immunizations with 1 × 109 TU of Lenti-HPV-07ind, Lenti-HPV-07nj or Ctrl Lentiind and TCRβ sequencing, performed on RNA extracted from peripheral blood cells. b Estimation of the TCRβ repertoire diversity using “true diversity” index. c Relative abundance of clonotypes, defined as their frequencies (X), compared to the total number of reads, which allows to divide the clonotypes into Small (0 < X ≤ 10–4), Medium (10–4 < X ≤ 10–3), Large (10–3 < X ≤ 10–2) and hyperexpanded (10–2 < X ≤ 100) categories. Relative abundance is the sum of the frequencies of all clonotypes from a given category. d Pie chart representing average proportions (mean) of Medium, Large and hyperexpanded categories in each group. e Follow up of the frequencies for the top 100 most abundant clonotypes, as defined at the post boost timepoint. f Classification of the top 100 most abundant clonotypes detected post boost, according to their expanding or contracting evolution since prime. New post boost clonotypes were defined from the comparison with top 100 post prime. Expanding or retracting/stabilizing clonotypes were defined as those having increasing or decreasing frequencies post boost respectively. g Frequencies of expanding or contracting clonotypes. Statistical significance was determined using a one-way ANOVA in (b) and, two-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001) in (c, f). Error bars on the histograms represent standard deviation.